AIMS: Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control. MATERIALS AND METHODS: We have studied 43 cancer patients who developed TE during cancer treatment (group 1); 81 cancer patients without TE (group 2); 100 patients with TE without malignancy (group 3); 100 healthy control (group 4). FVL and PT G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis. RESULTS: The prevalence of FVL was significantly greater in cancer patients with TE (13 of 43, 30.2%) compared with other groups: 3.7% in group 2; 18% in group 3; 8% in group 4 (P < 0.0001). There was no significant difference in the prevalence of PT G20210A among the groups (P > 0.05). CONCLUSIONS: The study suggested that cancer patients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.
AIMS: Cancerpatients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancerpatients with and without TE as compared to patients with TE without malignancy and healthy control. MATERIALS AND METHODS: We have studied 43 cancerpatients who developed TE during cancer treatment (group 1); 81 cancerpatients without TE (group 2); 100 patients with TE without malignancy (group 3); 100 healthy control (group 4). FVL and PT G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis. RESULTS: The prevalence of FVL was significantly greater in cancerpatients with TE (13 of 43, 30.2%) compared with other groups: 3.7% in group 2; 18% in group 3; 8% in group 4 (P < 0.0001). There was no significant difference in the prevalence of PT G20210A among the groups (P > 0.05). CONCLUSIONS: The study suggested that cancerpatients with TE should be evaluated for FVL but PT G20210A was not contributing factor to the development of TE during cancer therapy.
Authors: Eduardo Ramacciotti; Nelson Wolosker; Pedro Puech-Leao; Eduardo Antônio Zeratti; Paula Regina Gusson; Auro del Giglio; Rendrik F Franco Journal: Thromb Res Date: 2003-02-15 Impact factor: 3.944
Authors: M Mandalà; G Curigliano; P Bucciarelli; G Ferretti; P M Mannucci; M Colleoni; A Ventura; G Peruzzotti; G Severi; P G Pelicci; R Biffi; F Orsi; S Cinieri; A Goldhirsch Journal: Ann Oncol Date: 2004-04 Impact factor: 32.976
Authors: Olga V Gran; Erin N Smith; Sigrid K Brækkan; Hilde Jensvoll; Terry Solomon; Kristian Hindberg; Tom Wilsgaard; Frits R Rosendaal; Kelly A Frazer; John-Bjarne Hansen Journal: Haematologica Date: 2016-06-16 Impact factor: 9.941
Authors: F S Falvella; C Cremolini; R Miceli; F Nichetti; S Cheli; C Antoniotti; G Infante; A Martinetti; F Marmorino; E Sottotetti; R Berenato; M Caporale; A Colombo; F de Braud; M Di Bartolomeo; E Clementi; F Loupakis; F Pietrantonio Journal: Pharmacogenomics J Date: 2016-03-22 Impact factor: 3.550